Sanofi: Jefferies welcomes positive data for Dupixent

(CercleFinance.com) - Jefferies maintains its "buy" rating on Sanofi shares, along with its target price of E120, welcoming the release of positive Phase III data for its lead drug Dupixent in COPD (chronic obstructive pulmonary disease).


"Dupixent significantly reduced exacerbations and improved lung function in Phase III for COPD, with perhaps "best" case efficacy versus expectations, setting the stage to be the first biologic approved for this substantial market opportunity if the 2nd trial succeeds 1H24E," it said.

The broker points out that its sales estimate for Dupixent of E20bn by 2031 includes only E0.7bn for COPD, implying upside potential for the healthcare group's long-term EPS if successful.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.